Anupam Rasayan Completes ₹1,750 Crore Acquisition of 48.2% Stake in Bliss GVS Pharma, Entering Pharma Formulations

The Quick Take

• Anupam Rasayan completed a ₹1,750 crore acquisition of a 48.2% controlling stake in Bliss GVS Pharma via SPA at ₹299 per share
• The deal marks Anupam Rasayan's third strategic inorganic transaction as it diversifies from specialty chemicals into pharma formulations
• With a 50.07% stake post open offer, Anupam Rasayan gains full strategic control of Bliss GVS, a manufacturer of finished drug products

Anupam Rasayan India's completion of the ₹1,750 crore acquisition of a 48.2% stake in Bliss GVS Pharma represents a transformative strategic pivot for the Surat-based specialty chemicals and contract development company. By acquiring a controlling stake in a listed pharmaceutical formulations maker, Anupam Rasayan is building toward a vertically integrated position that spans specialty chemicals upstream to finished dosage forms downstream — a rare and strategically valuable combination in India's pharma supply chain. The deal was executed via the promoter Share Purchase Agreement route at ₹299 per share, with an open offer that pushed the total stake toward 50.07%.

The acquisition creates cross-selling opportunities between Anupam Rasayan's specialty chemicals and API manufacturing capabilities and Bliss GVS Pharma's finished drug production and distribution network. Indian specialty chemical-to-pharma integration stories have historically commanded significant market premiums, as the combined entity can offer one-stop solutions to multinational pharmaceutical clients. The current market capitalization of Anupam Rasayan at approximately ₹13,515 crore and the 0.12% decline in shares on the acquisition completion day suggests markets are in a 'wait and see' mode on synergy realization.

Watch Anupam Rasayan's integration timeline and the announced synergy plan — successful Bliss GVS integration in 12-18 months would validate the expansion thesis and likely trigger a re-rating of the combined entity. The US acquisition mentioned in source material (recent ahead of the Bliss deal) further extends the international footprint, and combined revenue guidance in the next quarterly results will be the quantified synergy signal investors are waiting for. The Indian pharma formulations sector's USFDA approval trajectory for Bliss GVS products is the highest-stakes quality signal.

Synthesized from 3 sources.